SETD2 loss-of-function mutations were found in 22% of patients with leukemia with rearrangements in the mixed-lineage leukemia gene (referred to as MLLr); altered histone methylation due to SETD2 knockdown transcriptionally downregulated tumor suppressors (ASXL1, ASXL2, BCOR) and upregulated oncogenes (ERG, STAT3, FNDC3A, NAMPT, IGF1R)78. The gene discussed is SETD2; the disease is leukemia.